Collaborative Drug Discovery Competitive Intelligence & Landscape

Collaborative Drug Discovery's mission is to deliver an unparalleled software experience for both humanitarian and commercial collaborative research and discovery [https://www.collaborativedrug.com/about]. The platform is designed to break down data silos by storing both biology and chemistry data in a single, flexible system, accommodating various data types and workflows. This approach significantly increases research productivity by enabling real-time collaboration and secure data access through any web browser, allowing teams to focus more on discoveries. Furthermore, CDD Vault safeguards intellectual property by protecting against data loss and unauthorized access, ensuring research assets are secure [https://www.collaborativedrug.com/].

The target market for Collaborative Drug Discovery spans various industries, including Biotech & Pharmaceutical companies, Contract Research Organizations (CROs), Academics, Agritechnology, Consortia & Collaborations, and Consumer Goods [https://www.collaborativedrug.com/]. The company serves a diverse range of user roles, from Research Scientists and Operations/IT personnel to Legal/Regulatory teams, Executive Leadership, Investors, and Startup Founders.

CDD's commitment to customer success is a core value, emphasizing that the success of their clients ultimately benefits the wider world of scientific discovery [https://www.collaborativedrug.com/about]. The company headquarters is in the US, with sales operations also in the UK [https://www.collaborativedrug.com/contact-us].

CDD Vault is offered with a free trial for virtual teams and also for specific applications like consumer goods R&D, allowing potential users to experience its capabilities, including managing complex R&D data and proprietary mixtures features. This trial option enables distributed research teams to organize chemical structures and biological study data intuitively, collaborating with internal or external partners through an easy-to-use web interface, anytime, anywhere. This strategy suggests a focus on demonstrating value before committing to a paid subscription.

The core functionality of CDD Vault includes registration for small molecules, biologics, and mixtures, activity visualization, assay data management, an integrated Electronic Lab Notebook (ELN), inventory management, and features for AI automation and curves. It supports applications for macrocycles, protein therapeutics, CRISPR, PROTAC, antibody drug conjugates, and small molecules, accommodating diverse research needs. The platform's emphasis on data structuring also facilitates AI applications and leverages built-in generative tools for discovering new leads, highlighting its advanced capabilities for modern drug discovery challenges. Pricing changes are not explicitly mentioned on the available sources, but the consistent availability of a free trial indicates a commitment to broad accessibility and user engagement.

A significant hiring trend at Collaborative Drug Discovery is the investment in Artificial Intelligence and Machine Learning capabilities. The company is actively seeking a Software Engineer for Informatics and Machine Learning to develop "cutting-edge AI capabilities within the CDD Vault platform" [collaborativedrug.com/software-engineer-informatics-machine-learnin]. This role is pivotal for the newest module of their twenty-year-old Ruby on Rails-based system, indicating a commitment to innovation and leveraging advanced technologies to further empower scientific research and drug discovery.

Beyond AI, Collaborative Drug Discovery is also bolstering its foundational technology and customer-facing teams. Openings include Senior Software Engineer positions, focusing on Ruby on Rails, React, TypeScript, MySQL, and Elasticsearch [collaborativedrug.com/senior-software-engineer], and a QA Automation Engineer to maintain their extensive browser-based test suite [collaborativedrug.com/qa-automation-engineer]. On the customer engagement front, they are looking for Business Development/Sales Professionals, Sales Account Administrators, and Pre-/Post-Sales Application Scientists for Asia, Europe, and the US [collaborativedrug.com/business-development-sales-professional-asia-europe-us], [collaborativedrug.com/sales-account-administrator-asia-europe-us], [collaborativedrug.com/application-scientist-asia-europe-us]. These roles, coupled with a Designer for application, front-end, and marketing tasks [collaborativedrug.com/designer-application-front-end-marketing], highlight a comprehensive strategy for both product innovation and market expansion.

Funding includes a notable $2,517,214 supplemental grant from the Bill & Melinda Gates Foundation in November 2022 to support data sharing and collaborative analytics for the Tuberculosis (TB) Drug Accelerator (TBDA) [Source: https://www.collaborativedrug.com/cdd-blog/cdd-announces-new-grant-supplement-for-tuberculosis-drug-accelerator]. This was complemented by an earlier $1,496,415 supplemental grant from the same foundation for the TBDA in October 2020 [Source: https://www.collaborativedrug.com/cdd-blog/cdd-announces-grant-commitment-tuberculosis-drug-discovery-scientists]. In February 2024, CDD received an additional $300,000 grant from the Bill & Melinda Gates Foundation specifically for advanced informatics capabilities to accelerate antimalarial antibody discovery [Source: https://www.collaborativedrug.com/cdd-blog/cdd-receives-malaria-antibody-data-management-grant].

Beyond philanthropic grants, Collaborative Drug Discovery has also been a successful recipient of competitive, peer-reviewed grants from the National Institutes of Health (NIH), particularly through the National Center for Advancing Translational Sciences (NCATS). These include a $1,709,776 grant in December 2022 for developing cloud workspaces for drug discovery [Source: https://www.collaborativedrug.com/cdd-blog/cdd-announces-new-nih-grant-to-develop-cloud-workspaces-for-drug-discovery], a $1.45 million grant in November 2022 to develop an intelligent chemical structure browser [Source: https://www.collaborativedrug.com/cdd-blog/cdd-announces-new-nih-grant-to-develop-intelligent-chemical-structure-browser], and an $880,000 grant in December 2022 for developing virtual approaches to new chemistries [Source: https://www.collaborativedrug.com/cdd-blog/cdd-announces-new-nih-grant-to-develop-virtual-approaches-to-new-chemistries].

Furthermore, CDD secured several Small Business Innovation Research (SBIR) Phase 2 grants, including a $1.5 million grant in April 2021 for an "Intelligent Chemical Structure Browser for Drug Discovery and Optimization" [Source: https://www.collaborativedrug.com/cdd-blog/cdd-awarded-phase-2-sbir-grant-intelligent-chemical-structure-browser-drug-discovery-optimization], an award in April 2020 for a "Novel deep learning strategy to better predict pharmacological properties of candidate drugs" [Source: https://www.collaborativedrug.com/cdd-blog/cdd-awarded-phase-2-sbir-grant-deep-learning-strategy-drug-discovery], and a grant in January 2020 for "Digital representation of chemical mixtures to aid drug discovery and formulation" [Source: https://www.collaborativedrug.com/cdd-blog/cdd-awarded-phase-2-sbir-grant-mixtures-formats-drug-discovery-formulation]. These consistent grant awards underscore CDD's financial health and its ongoing commitment to innovation in scientific data management and drug discovery informatics. The company was founded in 2004 by Barry Bunin as a spin-out from Eli Lilly, aiming to democratize collaborative research [Source: https://www.collaborativedrug.com/hubfs/llms.txt].

Beyond external conferences, Collaborative Drug Discovery fosters its community through dedicated scientific meetings. The CDD European Life Science Community Meeting is scheduled for February 25-26, 2026, in Cambridge, UK, featuring a community meeting day followed by an optional training day [https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026]. Similarly, the CDD Korean Life Science Community Meeting 2025 will take place on July 9, 2025, in Seoul, focusing on the evolving digital landscape in biotechnology [https://www.collaborativedrug.com/korea-seminar-2025]. The company also organizes localized events such as the CDD Life Sciences Community Event - South San Francisco 2026 and the CDD Vault User Group Meeting in San Diego, providing opportunities for users to connect, share insights, and learn about the latest product updates [https://www.collaborativedrug.com/upcoming-events], [https://www.collaborativedrug.com/cdd-vault-user-group-meeting-in-san-diego].

Collaborative Drug Discovery also extends its outreach through a robust webinar program, offering valuable insights into product updates and scientific advancements. Upcoming webinars in 2026 include the Eurasia and Americas Q2 2026 Product Update Webinars on June 11, and scientific discussions on topics such as "Assembly Modulation: A New Drug Discovery Strategy for CNS Diseases" on June 25, and "FDA Approvals of Aging Therapeutics: Current Status and Near-Term Pipeline" on July 23 [https://www.collaborativedrug.com/upcoming-webinars]. These webinars enable CDD to disseminate knowledge and connect with a global audience from various scientific backgrounds.

Looking ahead to 2025, Collaborative Drug Discovery will have a significant presence at several key drug discovery conferences. They will be part of the Discovery & Development/Drug Discovery US conference in San Diego on October 2-3, with James White presenting during the Novel Target ID track [https://www.collaborativedrug.com/discovery-development]. Janice Darlington will deliver a presentation on "AI-Enhanced, Chemically Aware Workflows" at the Precision in Drug Discovery & Preclinical Summit in San Diego on October 16-17 [https://www.collaborativedrug.com/pddp-2025]. Additionally, Susana Tomasio Ph.D. will present at DRUG DISCOVERY 2025 in Liverpool, United Kingdom, on October 21-22 [https://www.collaborativedrug.com/drug-discovery-2025]. These engagements highlight CDD's commitment to sharing expertise and demonstrating the capabilities of their CDD Vault platform in advancing drug discovery research.

Collaborative Drug Discovery also engages with the investor community, with Michael Woodhouse and Evan Moriarity attending the Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5-6, 2025. This event is vital for connecting with investors and industry leaders, further solidifying CDD's position in the healthcare technology sector [https://www.collaborativedrug.com/bloom-burton-co-healthcare-investor-conference].